Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
International Flavors & Fragrances (IFF): Turning the Corner on Profit Recovery Amid Conservative Guidance – Is the Outlook Sustainable and What Are the 5 Key Profit Catalysts?
International Flavors & Fragrances (IFF) delivered strong Q3 2024 results, with $2.93 billion in revenue (+9% currency-neutral growth), a $93.16M beat, and adjusted EBITDA rising 16% YoY to $567M (+180 bps margin expansion to 19.4%), driven by broad-based volume recovery and disciplined cost management. Scent achieved double-digit growth led by Fine Fragrance and Consumer categories, while Health & Biosciences (H&B) posted significant EBITDA growth on probiotics demand. Functional Ingredients showed early turnaround success with mid-single-digit volume growth and Pharma Solutions returned to growth, contributing an 8% revenue increase and 32% EBITDA surge ahead of its H1 2025 divestiture. Management raised FY24 guidance, with EBITDA projected at $2.17B and sales at $11.3-$11.4B, reflecting operational resilience despite macro headwinds like FX drags and customer inventory adjustments. Strategic investments in creative centers and deleveraging efforts (<3.0x net debt/EBITDA by FY25) enhance long-term potential, though near-term challenges persist with soft end-market demand and elevated variable costs. Tailwinds from inflation recovery, inventory normalization, and ongoing productivity gains reinforce profit growth into 2025. Can IFF sustain its recovery momentum while navigating conservative guidance and evolving customer demand to unlock long-term shareholder value?